Rocket Pharmaceuticals (Rocket Pharmaceuticals) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals 3-Year Revenue Growth Rate?

Rocket Pharmaceuticals's Revenue per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Rocket Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Rocket Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rocket Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Rocket Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Rocket Pharmaceuticals (NAS:RCKT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Rocket Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

9IP1:Germany

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Executives

John Militello	officer: See Remarks	C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker	director	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah	director, officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel	officer: Chief Operating Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White	officer: Chief Medical Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson	officer: General Counsel	C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada	officer: Chief Financial Officer	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork	director	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam	officer: SVP - Finance & PFO	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell	director, officer: See Remarks	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi	director	412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder	officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016